Oscar Izeboud, PhD
CEO20+ years of experience in biotech, including 14 years in investment banking at Kempen & Co and NIBC, leading over 50 IPO’s and M&A transactions across Europe and the USA.
Oscar joined Scenic in 2020 as CEO and is also a Board Director.
Prof. Sebastian Nijman
Founder & CSO20+ year career in Genomics research at leading academic institutions, including Oxford University and M.I.T..
10+ years of experience in biotech, including previous roles as CEO (Scenic) and COO (Haplogen).
Margot Hoppe
Head of Legal Affairs30+ years of experience in (corporate) legal affairs, having worked for various biotechnology and life sciences companies including Kiadis Pharma, Gist-Brocades and Royal DSM.
Prof. Stephen Friend
Scientific Advisory BoardStephen is a visionary leader in Genetics, Cancer, and Digital Health. He is recognized for cloning the first human cancer susceptibility gene and for proposing the utility of synthetic lethality for cancer therapy.
He co-founded and led Rosetta Impharmatics (acquired by Merck) to pioneer mRNA expression profiling for cancer. He was at Apple from 2014-2017 to work on digital health, he is now a co-founder and President of 4YouandMe, the Founder and Chairman of Sage Bionetworks, and is a Visiting Professor of Connected Medicine at the University of Oxford.
Prof. Chas Bountra
Scientific Advisory BoardChas is Pro-Vice Chancellor for Innovation and Professor of Translational Medicine at the University of Oxford.
He is Director of the Centre for Medicines Discovery in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.
Prof. Ton Schumacher
Scientific Advisory BoardTon is a world-leading expert in Immuno Oncology. He is a senior member at The Netherlands Cancer Institute and professor of Immunotechnology at Leiden University.
He is a founder of AIMM Therapeutics, T cell factory (acquired by Kite Pharma/Gilead), Neon Therapeutics (acquired by BioNTech), and Neogene. He is also a Third Rock Venture partner. His long list of awards include, The Amsterdam Inventor Award, Queen Wilhelmina Cancer Research Award, Meyenburg Cancer Research Award, William B. Coley Award and the Jeantet-Collen prize.
Prof. Thijn Brummelkamp
Founder & Scientific Advisory Board20+ year career in award-winning Genomics research. Group leader at The Netherlands Cancer Institute and former Fellow at the Whitehead Institute for Biomedical Research in Cambridge USA.
Co-founder of Haplogen, Haplogen Genomics and Scenic Biotech. Thijn is also a Scenic Board Observer.
Philippe Dro
Chairman of the BoardPhilippe has fulfilled leading roles in multiple biotech and medtech companies, including Themis Bioscience (acquired by Merck), GlycoVaxyn (acquired by GSK), Endoart (acquired by Allergan) and Axovan (acquired by Actelion).
Philippe serves on the Board of Luciole.
Oscar Izeboud, PhD
CEO20+ years of experience in biotech, including 14 years in investment banking at Kempen & Co and NIBC, leading over 50 IPO’s and M&A transactions across Europe and the USA.
Oscar joined Scenic in 2020 as CEO and is also a Board Director.
Alexandra Glucksmann, PhD
Independent Non-executive DirectorAlexandra is the President & CEO of Cedilla Therapeutics. Prior to that, she fulfilled multiple leadership roles including, VP at Millenium Pharmaceuticals, SVP at Cerulean Pharma, and most recently founding COO at Editas Medicine.
She also serves on the board of RegenxBio.
Roel Bulthuis
Non-executive DirectorRoel Bulthuis is a Managing Partner at INKEF Capital. Prior to joining INKEF he was SVP and Managing Director of M-Ventures, worked in business development at Merck Serono and in investment banking (Fortis Bank).
He serves on the boards of Comet Therapeutics, iOnctura, Onward, NMD Pharma, Salvia Bio, Electronicx, VarmX, Calypso and QurAlis.
Edward van Wezel
Non-executive DirectorEdward is Founder and Managing Partner at BioGeneration Ventures (BGV) and combines over 20 years of experience in venture capital, pharma licensing, drug development and translational research.
He was founding investor and board member of Acerta Pharma (acquired by Astra Zeneca for $7B) and currently serves on the boards of several BGV portfolio companies.
Nick Dixon-Clegg
Board ObserverNick serves on the board of Scenic as an Observer representing investor Oxford Sciences Enterprises. Nick works as an Investment Principal at Oxford Sciences Enterprises and brings experience from a career spent in investing and corporate finance.
Nick joined Oxford Sciences Enterprises from Valiance, a MedTech-focused venture capital firm. He was previously an investor at large cap buyout private equity firm Nordic Capital. Prior to that he began his career as an investment banker at Bank of America Merrill Lynch.
Stéphane Verdood
Non-executive DirectorStéphane Verdood has an MBA and a Master’s degree in commercial engineering from the Catholic University of Leuven. Stéphane is a recognized venture capitalist.
He started his career with Arthur Andersen as information technology auditor. After having led the mergers and acquisitions division of Arthur Andersen in Belgium from 1989 to 1995, he founded and led Arthur Andersen’s business consulting division in Belgium and Luxembourg. He served on the European Board of Partners of Arthur Andersen. Since October 2000, before he joined Vesalius Biocapital, Stéphane has been active as a venture coach for early-stage companies. He was a founder and managing partner at Value4Growth, a specialized Life Science consulting firm supporting start-up companies in all aspects of company formation, product strategy and fund raising.Stéphane is a founding partner of Vesalius Biocapital Funds specialized in venture capital for European biotechnology companies. Since 2007 Vesalius has invested in more than 20 biotech companies. During his career he has worked in the US, Switzerland, France, the Netherlands, the UK and Portugal. Fund raising to set up Fund I in 2007 and Fund II in 2011.
Michael Wacker
Non-executive DirectorMichael is an experienced life science entrepreneur and General Partner at BioMedPartners. Michael serves on the board of directors of various portfolio companies.
In addition, he coaches start-ups in Switzerland for Innosuisse, the governmental commission of technology and innovation. Before joining BioMedPartners, Michael was founder and CSO of GlycoVaxyn (acquired by GSK) and chairman of Inositec (acquired by Vifor).
Stephan Christgau, PhD
Non-executive DirectorStephan is founding partner of the Nordic Life Science Venture fund, Eir Ventures. Prior to launching Eir Ventures, Stephan was part of setting up Novo Seeds, the early stage company creation and investment arm of Novo Holdings.
During his 12 years at Novo Seeds, he led creation and funding of more than 25 companies in Europe, with a particular focus on Scandinavia. Stephan has extensive operational experience from management and research scientist roles in European and US Biotech and holds a PhD in Protein Chemistry and immunology from UCSF.
Prof. Thijn Brummelkamp
Founder & Board Observer20+ year career in award-winning Genomics research. Group leader at The Netherlands Cancer Institute and former Fellow at the Whitehead Institute for Biomedical Research in Cambridge USA.
Co-founder of Haplogen, Haplogen Genomics and Scenic Biotech. Thijn is also part of Scenic's Scientific Advisory Board.
